EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion

Leukemia

Volumn 28, Issue 9, 2014, Pages 1828-1837

  Aries I M ^a   Jerchel, I S ^a   Van Den Dungen, R E S R ^a   Van Den Berk, L C J ^a   Boer, J M ^a   Horstmann, M A ^b   Escherich, G ^b   Pieters, R ^a,c   Den Boer, M L ^a,c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ERYTHROCYTE MEMBRANE PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; PREDNISOLONE; SHORT HAIRPIN RNA; STAT3 PROTEIN; STAT5 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL MIGRATION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; EVENT FREE SURVIVAL; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T CELL LEUKEMIA;

APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; LEUKEMIA; NEOPLASM PROTEINS; NF-KAPPA B; PREDNISOLONE; PROGNOSIS; RECEPTORS, CELL SURFACE; SRC-FAMILY KINASES;

EID: 84908268971     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.80     Document Type: Article

References (39)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29: 551-565
2. Kaspers GJ, Pieters R, Van Zantwijk CH, VanWering ER, Van DerDoes-Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood. 1998; 92: 259-266
3. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hählen K., et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 1995; 86: 3861-3868
4. Kfir-Erenfeld S, Sionov RV, Spokoini R, Cohen O, Yefenof E. Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. Leuk Lymphoma. 2010; 51: 1968-2005
5. Taylor V, Welcher AA, Program AE, Suter U. Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. J Biol Chem. 1995; 270: 28824-28833
6. Bangsow T, Baumann E, Bangsow C, Jaeger MH, Pelzer B, Gruhn P., et al. The epithelial membrane protein 1 is a novel tight junction protein of the bloodbrain barrier. J Cereb Blood Flow Metab. 2008; 28: 1249-1260
7. Lee H-S, Sherley JL, Chen JJW, Chiu C-C, Chiou L-L, Liang J-D., et al. EMP-1 is a junctional protein in a liver stem cell line and in the liver. Biochem Biophys Res Commun. 2005; 334: 996-1003
8. Ben-Porath I, Yanuka O, Benvenisty N. The tmp gene, encoding a membrane protein, is a c-Myc target with a tumorigenic activity. Mol Cell Biol. 1999; 19: 3529-3539
9. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD., et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005; 65: 8679-8689
10. Turashvili G, Bouchal J, Ehrmann J, Fridman E, Skarda J, Kolar Z. Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. Biomed Papers. 2007; 151: 59-64
11. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A., et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci USA. 2005; 102: 11858-11863
12. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJP, Kazemier KM., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004; 351: 533-542
13. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Körholz D., et al. Patient stratification based on prednisolone-vincristine-Asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003; 21: 3262-3268
14. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, JGCAM Buijs-Gladdines, STCJM Peters., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009; 10: 125-134
15. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E., et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol. 2003; 120: 846-849
16. Huber W, von Heydebreck A, Sü ltmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002; 18(Suppl 1): S96-S104
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995; 57: 289-300
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509
19. de Wreede LC, Fiocco M, Putter H. mstate: an R package for the analysis of competing risks and multi-state models. J Stat Softw. 2011; 38
20. Gray R. Cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-2 2011
21. Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O., et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood. 2011; 117: 902-914
22. Iwamoto S, Mihara K, Downing JR, Pui C-H, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Investig. 2007; 117: 1049-1057
23. Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res. 2008; 101: 127-248
24. Pieters R, Kaspers GJ, van Wering ER, Huismans DR, Loonen AH, Hählen K., et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia. 1993; 7: 392-397
25. Désarnaud F, Bidichandani S, Patel PI, Baulieu E-E, Schumacher M. Glucocorticosteroids stimulate the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. Brain Res. 2000; 865: 12-16
26. Wadehra M, Mainigi M, Morales SA, Rao RG, Gordon LK, Williams CJ., et al. Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod Biol Endocrinol. 2008; 6: 15
27. Li Z-Y, Xiong S-H, Hu M, Zhang C-S. Epithelial membrane protein 1 inhibits human spinal chondrocyte differentiation. Anat Record. 2011; 294: 1015-1024
28. Ben-Porath I, Benvenisty N. Characterization of a tumor-Associated gene, a member of a novel family of genes encoding membrane glycoproteins. Gene. 1996; 183: 69-75
29. Sison EAR, Brown P. The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol. 2011; 4: 271-283
30. Masson K, Rönnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal. 2009; 21: 1717-1726
31. Lai S, Wang G, Cao X, Li Z, Hu J, Wang J. EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway. J Huazhong Univ Sci Technol Med Sci. 2012; 32: 834-838
32. Morales SA, Mareninov S, Coulam P, Wadehra M, Goodglick L, Braun J., et al. Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2). Investig Ophthalmol Vis Sci. 2009; 50: 4949-4956
33. Gauld SB, Cambier JC. Src-family kinases in B-cell development and signaling. Oncogene. 2004; 23: 8001-8006
34. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004; 23: 7990-8000
35. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene. 2004; 23: 8017-8023
36. Quintas-Cardama A, Verstovsek S. Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013; 19: 1933-1940
37. Malin S, McManus S, Busslinger M. STAT5 in B cell development and leukemia. Curr Opin Immunol. 2010; 22: 168-176
38. Mangolini M, de Boer J, Walf-Vorderwü lbecke V, Pieters R, den Boer ML, Williams O. STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia. Blood. 2013; 122: 542-549
39. Pignatello R, Musumeci T, Basile L, Carbone C, Puglisi G. Biomembrane models and drug-biomembrane interaction studies: Involvement in drug design and development. J Pharm Bioallied Sci. 2011; 3: 4-14